GlassScriptPhysician profile
Anna Marcy Kiihnl
NPI 1346896123
$3,665.61
in general payments reported to CMS, 2019-2025
27 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $732 · 2023: $460 · 2024: $1,113 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,392.13 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.97 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $197.98 | 2022-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $188.89 | 2022-2025 | Entyvio |
| Janssen Biotech, INC. | $136.98 | 2023-2025 | Tremfya, Stelara, Remicade |
| Mirum Pharmaceuticals, INC. | $129.75 | 2025 | Livmarli |
| Genzyme Corporation | $121.22 | 2024-2025 | |
| Ardelyx, INC. | $117.62 | 2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $117.33 | 2022-2023 | |
| Qol Medical, LLC | $113.31 | 2022-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $106.30 | 2022-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $92.64 | 2022-2024 | Linzess |
| Vivus LLC | $66.27 | 2024-2025 | Pancreaze, Qsymia |
| Aimmune Therapeutics, INC. | $53.89 | 2024-2025 | Zenpep |
| Shield Therapeutics INC | $49.03 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $42.71 | 2025 | Voquezna |
| Boston Scientific Corporation | $42.58 | 2025 | General - Therapies, Wavewriter Alpha Prime 16 |
| Evoke Pharma, INC. | $41.30 | 2022-2025 | |
| Madrigal Pharmaceuticals | $36.88 | 2025 | Rezdiffra |
| Lilly USA, LLC | $35.01 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $22.54 | 2022 | |
| Gilead Sciences, INC. | $20.46 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.28 | 2023 | Cyltezo |
| Amag Pharmaceuticals, INC. | $16.14 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.56 | 2024 | Givlaari |
| Celltrion USA INC. | $14.65 | 2025 | Vegzelma |
| Pfizer INC. | $14.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kiihnl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.